JAK2 and myeloproliferative neoplasm: The detailed analysis of MPN patients regarding to their JAK2V617F allele status and the PAR1 expression were performed including four patients carrying monoallelic JAK2V617F, five patients bi-allelic JAK2V617F and two wild type JAK2 patients and did not revealed any significant difference in a such comparison (Fig. 4J).